An amylin analog used as a challenge test for Alzheimer's disease.

At baseline, the MCI group tended to have a lower concentration of plasma amylin than did the control or AD group, but the difference did not reach statistical significance ( Supplementary Fig. 1A ).

also in 111,027 other papers